Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

BHP flags $1.7bn cost overrun at Canada fertiliser project

(Sharecast News) - Australian mining giant BHP flagged a cost overrun of up to $1.7 billion at its Jansen potash fertiliser project in Canada and also reported record copper and iron ore output. The company also flagged a delay in first production to mid-2027 and said it now expected to spend between $7bn - $7.4bn for the first stage of the Jansen project, from an original estimate of $5.7bn.

BHP cited inflation and design changes, leading to cost increases and delays, for the budget blowout. The company is betting on the project as it tries to diversify away from iron ore and coal.

Copper output hit a record high of 2.02 million metric tons (Mt) in the 2025 fiscal year. However, it expected this to fall to between 1.8 Mt and 2.0 Mt next year, due to planned lower grades at its flagship Escondida mine in Chile.

Iron ore production at its Western Australia operation came in at 290 Mt for the year, also a record high.

BHP also said it was looking at a potential divestment of its Western Australia nickel assets as part of a review, citing balance sheet impacts from the nickel business.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.